NEW HAVEN, Conn.--(BUSINESS WIRE)--Kolltan Pharmaceuticals, Inc., a privately held clinical-stage company focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs), today announced the presentation of preclinical data showing that KTN3379 reverses ErbB3-mediated resistance of BRAF and MEK inhibitors in BRAF-mutated thyroid cancer and melanoma. KTN3379 is a potent, human anti-ErbB3 (HER3) monoclonal antibody drug candidate in Phase 1b clinical trials being developed for the treatment of adult patients with various solid tumors.
Help employers find you! Check out all the jobs and post your resume.
